The Importance of Outcome Measures in the Management of Inflammatory Rheumatic Diseases

References

• Castrejon I, McCollum L, Tanriover MD, Pincus T. Importance of patient history and physical examination in rheumatoid arthritis compared to other chronic diseases: results of a physician survey. Arthritis Care Res (Hoboken). 2012;64(8):1250–1255. doi:10.1002/acr.21650
   Web of Science ®Google Scholar
• Castrejon I, Gossec L, Carmona L. The EULAR Outcome Measures Library: an evolutional database of validated patient-reported instruments. Ann Rheum Dis. 2015;74(2):475–476. doi:10.1136/annrheumdis-2014-206485
   Web of Science ®Google Scholar
• Rose HM, Ragan C, et al. Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. Proc Soc Exp Biol Med Soc Exp Biol Med. 1948;68(1):1–6.
   Web of Science ®Google Scholar
• Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Meta-Analysis Research Support, Non-U.S. Gov’t Review. Ann Intern Med. 2007;146(11):797–808.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–1588.
   PubMed Web of Science ®Google Scholar
• Pincus T, Castrejon I. Are patient self-report questionnaires as “scientific” as biomarkers in “treat-to-target” and prognosis in rheumatoid arthritis? Curr Pharm Des. 2015;21(2):241–256.
   Web of Science ®Google Scholar
• Verhoeven AC, Boers M, van Der Linden S. Responsiveness of the core set, response criteria, and utilities in early rheumatoid arthritis. Ann Rheum Dis. 2000;59(12):966–974. doi:10.1136/ard.59.12.966
   Web of Science ®Google Scholar
• Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–977. doi:10.1136/annrheumdis-2016-210715
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1–25. doi:10.1002/acr.22783
   PubMed Web of Science ®Google Scholar
• van der Heijde DM, van ‘T Hof M, Van riel PL, Van de putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 1993;20(3):579–581.
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–48.
   PubMed Web of Science ®Google Scholar
• Castrejon I, Ortiz AM, Garcia-Vicuna R, et al. Are the C-reactive protein values and erythrocyte sedimentation rate equivalent when estimating the 28-joint disease activity score in rheumatoid arthritis? Comparative Study Research Support, Non-U.S. Gov’t. Clin Exp Rheumatol. 2008;26(5):769–775.
   Web of Science ®Google Scholar
• Castrejon I, Ortiz AM, Toledano E, et al. Estimated cutoff points for the 28-joint disease activity score based on C-reactive protein in a longitudinal register of early arthritis. Research Support, Non-U.S. Gov’t. J Rheumatol. 2010;37(7):1439–1443. doi:10.3899/jrheum.091333
   Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42(2):244–257.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S100–8.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796–806.
   PubMed Web of Science ®Google Scholar
• Pincus T, Yazici Y, Bergman MJ. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin North Am. 2009;35(4):773–8, viii.
   PubMed Web of Science ®Google Scholar
• Castrejon I, Bergman MJ, Pincus T. MDHAQ/RAPID3 to recognize improvement over 2 months in usual care of patients with osteoarthritis, systemic lupus erythematosus, spondyloarthropathy, and gout, as well as rheumatoid arthritis. Research Support, Non-U.S. Gov’t. J clin rheumatol. 2013;19(4):169–174. doi:10.1097/RHU.0b013e3182936b98
   Web of Science ®Google Scholar
• Castrejon I, Pincus T. Patient self-report outcomes to guide a treat-to-target strategy in clinical trials and usual clinical care of rheumatoid arthritis. Clin Exp Rheumatol. 2012;30(Suppl. 73):S50–S55.
   Google Scholar
• Ward MM, Castrejon I, Bergman MJ, Alba MI, Guthrie LC, Pincus T. Minimal clinically important improvement of routine assessment of patient index data 3 in rheumatoid arthritis. J Rheumatol. 2019;46(1):27–30. doi:10.3899/jrheum.180153
   Web of Science ®Google Scholar
• Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70(3):404–413. doi:10.1136/ard.2011.149765
   PubMed Web of Science ®Google Scholar
• Castrejon I, Dougados M, Combe B, Guillemin F, Fautrel B, Pincus T. Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort. Research Support, Non-U.S. Gov’t. J Rheumatol. 2013;40(4):386–393. doi:10.3899/jrheum.121059
   Web of Science ®Google Scholar
• Castrejon I, Dougados M, Combe B, Fautrel B, Guillemin F, Pincus T. Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other core data set measures, but not by the absence of rheumatoid factor, anticitrullinated protein antibodies, or radiographic erosions. J Rheumatol. 2016;43(7):1285–1291. doi:10.3899/jrheum.141586
   Web of Science ®Google Scholar
• Machado PM, Raychaudhuri SP. Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis. Best Pract Res Clin Rheumatol. 2014;28(5):711–728. doi:10.1016/j.berh.2014.10.004
   Web of Science ®Google Scholar
• Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Suppl 2):ii1–44. doi:10.1136/ard.2008.104018
   PubMed Web of Science ®Google Scholar
• Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. Comparative Study Research Support, Non-U.S. Gov’t. J Rheumatol. 1994;21(12):2286–2291.
   PubMed Web of Science ®Google Scholar
• Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2003;62(9):817–824.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(6):905–908. doi:10.1136/ard.2011.151563
   PubMed Web of Science ®Google Scholar
• Cohen JD, Cunin P, Farrenq V, et al. Estimation of the Bath Ankylosing Spondylitis Disease Activity Index cutoff for perceived symptom relief in patients with spondyloarthropathies. J Rheumatol. 2006;33(1):79–81.
   Web of Science ®Google Scholar
• Godfrin-Valnet M, Prati C, Puyraveau M, Toussirot E, Letho-Gyselink H, Wendling D. Evaluation of spondylarthritis activity by patients and physicians: ASDAS, BASDAI, PASS, and flares in 200 patients. Joint Bone Spine. 2013;80(4):393–398. doi:10.1016/j.jbspin.2013.01.003
   PubMed Web of Science ®Google Scholar
• Song IH, Rudwaleit M, Listing J, Sieper J. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Ann Rheum Dis. 2009;68(11):1701–1707. doi:10.1136/ard.2008.099226
   Web of Science ®Google Scholar
• Spoorenberg A, van Tubergen A, Landewe R, et al. Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology (Oxford). 2005;44(6):789–795. doi:10.1093/rheumatology/keh595
   Web of Science ®Google Scholar
• Lukas C, Landewe R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Validation Studies. Ann Rheum Dis. 2009;68(1):18–24. doi:10.1136/ard.2008.094870
   PubMed Web of Science ®Google Scholar
• Machado P, van der Heijde D. How to measure disease activity in axial spondyloarthritis? Research Support, Non-U.S. Gov’t Review. Curr Opin Rheumatol. 2011;23(4):339–345. doi:10.1097/BOR.0b013e3283470f23
   Web of Science ®Google Scholar
• Fernandez-Espartero C, de Miguel E, Loza E, et al. Validity of the ankylosing spondylitis disease activity score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme. Ann Rheum Dis. 2014;73(7):1350–1355. doi:10.1136/annrheumdis-2012-202976
   Web of Science ®Google Scholar
• Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44(8):1876–1886. doi:10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F
   PubMed Web of Science ®Google Scholar
• Sieper J. How to define remission in ankylosing spondylitis? Ann Rheum Dis. 2012;71 Suppl 2:i93–5. doi:10.1136/annrheumdis-2011-200798
   Web of Science ®Google Scholar
• Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010;69(8):1441–1447. doi:10.1136/ard.2009.122259
   Web of Science ®Google Scholar
• Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011;70(2):272–277. doi:10.1136/ard.2010.129379
   PubMed Web of Science ®Google Scholar
• FitzGerald O, Helliwell P, Mease P, et al. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. Ann Rheum Dis. 2012;71(3):358–362. doi:10.1136/annrheumdis-2011-200093
   Web of Science ®Google Scholar
• Coates LC. Treating to target in psoriatic arthritis. Curr Opin Rheumatol. 2015;27(2):107–110. doi:10.1097/BOR.0000000000000140
   Web of Science ®Google Scholar
• Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69(1):48–53. doi:10.1136/ard.2008.102053
   PubMed Web of Science ®Google Scholar
• Castrejon I, Pincus T, Wendling D, Dougados M. Responsiveness of a simple RAPID-3-like index compared to disease-specific BASDAI and ASDAS indices in patients with axial spondyloarthritis. RMD Open. 2016;2(2):e000235. doi:10.1136/rmdopen-2015-000235
   Google Scholar
• Coates LC, Tillett W, Shaddick G, Pincus T, Kavanaugh A, Helliwell PS. Value of the routine assessment of patient index data 3 in patients with psoriatic arthritis: results from a tight-control clinical trial and an observational cohort. arthritis care res (hoboken). 2018;70(8):1198–1205. doi:10.1002/acr.23460
   Web of Science ®Google Scholar
• Castrejon I, Tani C, Jolly M, Huang A, Mosca M. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care. Clin Exp Rheumatol. 2014;32 Suppl 85(5):85–95.
   Web of Science ®Google Scholar
• Arora S, Isenberg DA, Castrejon I. Measures of adult systemic lupus erythematosus: disease activity and damage. Arthritis Care Res (Hoboken). 2020;72(Suppl 10):27–46. doi:10.1002/acr.24221
   Web of Science ®Google Scholar
• Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005;44(7):902–906. doi:10.1093/rheumatology/keh624
   PubMed Web of Science ®Google Scholar
• Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288–291.
   PubMed Web of Science ®Google Scholar
• Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363–369.
   PubMed Web of Science ®Google Scholar
• Karlson EW, Daltroy LH, Rivest C, et al. Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies. Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S. Validation Studies. Lupus. 2003;12(4):280–286.
   PubMed Web of Science ®Google Scholar
• Petri M, Barr SG, Buyon J, Davis A, Ginzler E, Kalunian K. RIFLE: responder Index for Lupus Erythematosus [abstract]. Arthritis Rheum. 2000;43(Suppl 9):S244.
   Google Scholar
• Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61(9):1143–1151. doi:10.1002/art.24698
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014;73(1):183–190. doi:10.1136/annrheumdis-2012-202760
   PubMed Web of Science ®Google Scholar
• Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Consensus Development Conference Practice Guideline. Ann Rheum Dis. 2010;69(7):1269–1274. doi:10.1136/ard.2009.117200
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958–967. doi:10.1136/annrheumdis-2013-205139
   PubMed Web of Science ®Google Scholar
• van Gestel AM, Anderson JJ, van Riel PL, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol. 1999;26(3):705–711.
   Web of Science ®Google Scholar
• Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol. 2008;35(11):2136–2147.
   PubMed Web of Science ®Google Scholar